Biologic Therapies for Giant Cell Arteritis

Glucocorticoids have been the mainstay of treatment in giant cell arteritis (GCA) for the past 70 years. Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) have largely failed to show significant clinical efficacy or reduction of the glucocorticoid burden in GCA. Tocilizumab is...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrington, Robert, Al Nokhatha, Shamma Ahmad, Conway, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797292/
https://www.ncbi.nlm.nih.gov/pubmed/33442231
http://dx.doi.org/10.2147/BTT.S229662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797292/
https://www.ncbi.nlm.nih.gov/pubmed/33442231
http://dx.doi.org/10.2147/BTT.S229662

Ejemplares similares